Adjuvant hormonal therapy for early-stage breast cancer

Surgical Oncology Clinics of North America

Volumn 19, Issue 3, 2010, Pages 639-647

  Burstein, Harold J ^a   Griggs, Jennifer J ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Adjuvant endocrine therapy; Aromatase inhibitors; Ovarian suppression; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN RECEPTOR; EXEMESTANE; GONADORELIN DERIVATIVE; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE;

AMENORRHEA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FRAGILITY FRACTURE; HOT FLUSH; HUMAN; MENOPAUSAL SYNDROME; MENSTRUAL IRREGULARITY; MONOTHERAPY; NIGHT SWEAT; OSTEOPENIA; OSTEOPOROSIS; OVARIECTOMY; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VAGINA ATROPHY; VAGINA DISCHARGE; VAGINAL DRYNESS; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE; HORMONE SUBSTITUTION;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS;

EID: 77954159674     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2010.03.006     Document Type: Review

References (41)

1. Fisher B., Bryant J., Dignam J.J., et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002, 20(20):4141-4149.
2. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 2001, 30:5-15.
3. Goldhirsh A., Ingle J.N., Gelber R.D. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20(8):1319-1329.
4. Carlson R.W., Allred D.C., Anderson B.O., et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009, 7(2):122-192.
5. Fisher B., Anderson S., Tan-Chiu E., et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001, 19(4):931-942.
6. Allred D.C., Carlson R.W., Berry D.A., et al. NCCN task force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw 2009, 7(Suppl 6):S1-21.
7. Saphner T., Tormey D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996, 14(10):2738-2746.
8. Love R.R., Van Dinh N., Quy T.T., et al. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. J Clin Oncol 2008, 26:253-257.
9. Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998, 339:1609-1618.
10. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
11. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001, 93(9):684-690.
12. Smith I.E., Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003, 348(24):2431-2442.
13. Geisler J., Helle H., Ekse D., et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res 2008, 14(19):6330-6335.
14. Hudis C.A., Barlow W.E., Costantino J.P., et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007, 25:2127-2132.
15. Dowsett M., Cuzick J., Ingle J., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010, 28(3):509-518.
16. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005, 23:619-629.
17. Eastell R., Adams J.E., Coleman R.E., et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008, 26:1051-1057.
18. Brufsky A., Bundred N., Coleman R., et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008, 13(5):503-514.
19. Van Posnack C., Hannon R.A., Mackey J.R., et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010, 28(No 6):967-975.
20. Burstein H.J., Winer E.P. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol 2007, 25:3797-3799.
21. Mouridsen H., Keshaviah A., Coates A.S., et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 2007, 25:5715-5722.
22. Higgins M.J., Rae J.M., Flockhart D.A., et al. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?. J Natl Compr Canc Netw 2009, 7(2):203-213.
23. Mauriac L., Keshaviah A., Debled M., et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007, 18:859-867.
24. Dowsett M., Cuzick J., Wale C., et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010, 28(11):1829-1834.
25. Smith I.E., Dowsett M., Yap Y.S., et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006, 24:2444-2447.
26. Parton M., Smith I.E. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women. J Clin Oncol 2008, 26(5):745-752.
27. Davidson N.E., O'Neill A.M., Vukov A.M., et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005, 23(25):5973-5982.
28. International Breast Cancer Study Group, Colleoni M., Gelber S., et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006, 24(9):1332-1341.
29. LHRH-agonists in Early Breast Cancer Overview group 3, Cuzick J., Ambroisine L., et al. Use of lueinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor positive breast cancer: a meta-analysis of individual patient data from randomized adjuvant trials. Lancet 2007, 369:1711-1723.
30. Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2003, 359:2131-2139.
31. Forbes J.F., Cuzick J., Buzdar A., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9:45-53.
32. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B., Keshaviah A., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353(26):2747-2757.
33. Mouridsen H., Giobbie-Hurder A., Goldhirsch A., et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361:766-776.
34. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
35. Bliss JM, Kilburn LS, Coleman RE, et al. Disease related outcome with long term follow-up: an updated analysis of the Intergroup Exemestaine Study (IES). Presented at the 2009 San Antonio Breast Cancer Symposium. December, 2009.
36. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092.
37. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366:455-462.
38. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005, 23:5138-5147.
39. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802.
40. Jakesz R., Greil R., Gnant M., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007, 99(24):1845-1853.
41. Mamounas E.P., Jeong J.H., Wickerham D.L., et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 2008, 26:1965-1971.